Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568162 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Ichnos Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 462
- Enrollment target
NCT03568162 is a Phase 2 study that has completed, run by Ichnos Sciences. The registered enrollment target is 462 participants.
The verdict
NCT03568162, a Phase 2 study, has completed, sponsored by Ichnos Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 462 participants
- Enrollment target
Study Summary
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis. The study will be conducted in 2 Parts, with dosing Groups 1-4 comprising Part 1, and dosing Groups 5-6 comprising Part 2. All subjects will receive open-label ISB 830 after a 16 week blinded treatment period.
Interventions
- DRUG ISB 830 - Part 1 Group 1
- DRUG ISB 830 - Part 1 Group 2
- DRUG ISB 830 - Part 1 Group 3
- DRUG Placebo - Part 1 Group 4
- DRUG ISB 830 - Part 2 Group 5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2018-05-31 |
| Est. Completion | 2021-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03568162
The ClinicalTrials.gov registry entry for NCT03568162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ichnos Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ISB 830 - Part 1 Group 1 is the first listed.
NCT03568162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03568162 about?
NCT03568162 is a clinical study titled "Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis". Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis. The study will be conducted in 2 Parts, with dosing Groups 1-4 comprising Part 1, and dosing Groups 5-6 ...
What is the current status of trial NCT03568162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 462 participants. The study started on 2018-05-31. Estimated completion is 2021-08-03.
What interventions are being tested in trial NCT03568162?
The interventions under investigation include: ISB 830 - Part 1 Group 1 (DRUG), ISB 830 - Part 1 Group 2 (DRUG), ISB 830 - Part 1 Group 3 (DRUG), Placebo - Part 1 Group 4 (DRUG), ISB 830 - Part 2 Group 5 (DRUG).
Who is sponsoring clinical trial NCT03568162?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.